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ABSTRACT  
 
 
The Notch1 signaling pathway has  a pivotal role in cell fate regulation and  has been found to be 
critically deranged in different cancers, including colorectal cancer (CRC). Inflammation is known 
to play an important role in the pathogenesis of CRC and a prominent function of Notch1 during 
inflammation has been recently demonstrated. Epithelial to Mesenchymal Transition (EMT), a 
crucial process in the malignant transformation, is modulated by inflammation and 
Metalloproteinase-9 (MMP9) is involved in this interaction. Eicosapentaenoic Acid is an omega-3 
polyunsaturated fatty acid (-3 PUFA) known for its anti-inflammatory properties as well as for its 
capability in preventing colon cancer development both in sporadic and in hereditary settings. In 
particular, our group has demonstrated that an extra-pure formulation of Eicosapentaenoic Acid as 
the free fatty acid (EPA-FFA) protects from CRC development in a mouse model of colitis-
associated cancer (CAC) by modulating the Notch signaling pathway. In the present work, we re-
created an in vitro model of inflammatory-driven CRC by exposing colon cancer cells to a 
cytokine-enriched conditioned medium (CM) obtained from THP-1-differentiated macrophages. 
We found, for the first time, that CM strongly induces Notch1 signaling and EMT markers, 
increasing the capability of cells to invade. Importantly we found that, upon CM exposure, Notch1 
signaling is dependent on MMP9 expression. Finally, we show that a non-cytotoxic pre-treatment 
with 50 μM of EPA-FFA for 72h counteracts the effect of inflammation on Notch1 signaling and 
EMT, leading to a reduction of invasiveness. Taken together, our data demonstrate that in CRC 
inflammation up-regulates Notch1 signaling through MMP9 and that this mechanism can be 
effectively counteracted by EPA-FFA. 
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1. INTRODUCTION 
 
1.1 Colorectal Cancer (CRC) 
 
Colorectal cancer (CRC) is a malignant transformation that affects the first and the final sections of 
the large intestine, namely the colon and the rectum (1). CRC represents the third most common 
type of cancer and the fourth leading cause of cancer-related death worldwide, with more than a 
million of newly diagnosed cases every year (2). The majority of colorectal cancers (85-90%) 
occurs sporadically,  actually without a clearly recognizable predisposition, while a smaller 
percentage of cases is attributable to familial or hereditary forms (2-5%) or to the persistence of 
inflammatory conditions (1-2 %), (Figure 1), (3). An important non-modifiable risk factor for CRC 
is represented by the increasing age: more than 90% of the new cases are diagnosed among people 
aged 55 years or more (4). Importantly, many CRC risk factors are modifiable factors connected to 
the dietary habits (i.e. obesity), smoking or alcohol consumption (5). The high incidence of the 
sporadic form of CRC outlines the substantial effect of the environment on the pathogenesis (6). 
Indeed, the probability to develop CRC changes in relation to the geographical distribution: the 
highest incidence is found in economically developed countries, in particular Australia/New 
Zealand, United States and Europe, while the lower incidence is found in Africa and South-Central 
Asia (Figure 2), (3).  
 
Figure 1: Subtypes of Colorectal Cancer. FAP= familial adenomatous polyposis; HNPCC = 
hereditary non-polyposis colorectal cancer. Modified from Bart 2000, (7). 
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Figure 2: Age-Standardized Colorectal Cancer Incidence Rates by Sex and World Area. From 
GLOBOCAN 2008, (3). 
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1.1.1 Colorectal carcinogenesis 
 
The gut epithelium is a highly proliferative organ, with a substantial  cellular turnover. Homeostasis 
is achieved by a fine balance among cellular proliferation, differentiation and death (8). The 
colorectal carcinogenesis arises from a disruption of this delicate balance. In particular, the 
interplay between environmental factors and susceptibility genes sets off a complex series of 
neoplastic events. In 1990, Fearon and Vogelstein proposed a multistep adenoma-to-carcinoma 
model for colorectal tumorigenesis, based on the assumption that a cell must accumulate a specific 
sequence of genetic alterations in order to undergo full malignant transformation (9). Elevated rate 
of crypt fission, defined as aberrant crypt foci (ACF) is considered the first detectable defect in pre-
neoplastic intestine by which microadenomas develop (10). Sustained by a pro-tumorigenic 
microenvironment, which promotes the acquisition of additional mutations, a small part of ACF can 
evolve toadenoma and then to colorectal carcinoma (Figure 3).  
The genetic mutations crucial for the carcinogenic process affect fundamentally three types of 
genes: 1) proto-oncogenes 2) tumor suppressor genes  3) DNA repair genes (11). Proto-oncogenes, 
such as K-RAS, are activated into oncogenes even by a single “gain of function” mutation; this 
activation results in the capability for the cell to grow in the absence of growth factors but also in  
 
 
Figure 3: The Adenoma to Carcinoma sequence, modified from Guruswamy and Rao 2008, (12). 
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abnormal invasion capability and in the disruption of the apoptosis mechanism (13). Tumor 
suppressor genes, such as APC or p53, require two genetic events (one in each allele), for their 
inactivation resulting in a “loss of function”. Finally, alterations in DNA repair genes, such as  
SMAD4, that normally preserve newly replicated DNA from errors by repairing mismatched bases 
in the molecule, result in an abnormal accumulation of  mutations (14).  
The Adenomatous Polyposis Coli (APC) is considered the driver gene in the pathogenesis of CRC 
and is mutated in approximately 85% of cases (15). APC controls the WNT/ β-catenin signaling 
pathway: inactivating mutations in APC lead to stabilization of β-catenin and nuclear translocation, 
which in turn leads to the transcription of downstream oncogenes such as CYCLIN-D1 and C-MYC 
(16).  
In this context, the above-mentioned genetic events interact with epigenetic mechanisms, inducing 
the acceleration of the accumulation of mutations. The principal epigenetic mechanisms involved  
in the ethiopathogenesis of the CRC are: the chromosomal instability (CIN),  the CpG island 
methylator phenotype (CIMP) and deficiency of genes of the DNA mismatch repair system (MMR), 
(17). CIN consists in an elevated frequencies of whole-chromosome missegregation that leads to 
chromosomal imbalance, namely aneuploidy, and  is a predominant pathway in CRC since it occurs 
in 85% of the cases (18). The CIMP, which includes also sporadic microsatellite instability (MSI), 
represents the aberrant methylation of entire regions or CG sequences found in  the promoter of 
genes, and is associated with the downregulation/loss of their expression; up to 15% of the cases of 
CRC present a CIMP phenotype (19). Then,  the MMR pathway, tipically resulting from a germline 
mutation in the DNA of the mismatch repair (MMR) genes such as MSH2, MLH1, MSH6 and 
PMS2, allows persistence of mismatch mutations all over the genome (20). 
1.1.2 Sporadic Colorectal Cancer  
 
Most CRC (70%) develop as sporadic cancers, since one or more precise involved genes are not 
identifiable. A colorectal epithelial cell generally requires about 20-40 years to transform into a 
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metastatic tumor cell (15). In the classic 'adenoma-carcinoma' model, mutations in APC gene or 
loss of chromosome 5q (which includes the APC gene) are an early event,  followed by mutations in 
KRAS, which generally occur in the intermediate adenoma stage. Then, a later event occurring 
during the malignant transformation from adenoma to carcinoma in situ is the mutation or LOH of 
p53 gene or deletions of chromosome 17p (which includes the p53 gene), (21). After the molecular 
characterization of CRC proposed by Fearon and Vogelstein, in the following decades of research it 
has been demonstrated that only 6.6% of CRC tumors is characterized by concurrent mutations in 
APC, KRAS and p53, while 38% of tumors had mutations in only one of these three genes (13). 
These observations led to consider the development of CRC in a more complex view. Indeed, 
alterations in additional pathways, as well as epigenetic changes in cancer related genes and 
modulation of non-coding RNA importantly contribute to the malignant transformation (22). 
1.1.3 Familial and Hereditary Colorectal Cancer  
 
Epidemiological studies indicate that approximately 15% of CRC occur in inherited patterns (23). 
Typically, hereditary CRC occurs upon an inherited predisposition and are characterized by germ-
line mutations which confer a major risk to develop CRC at an earlier age of onset respect to the 
sporadic forms (24). According to the presence or absence of polyposis, the hereditary forms of 
CRC are classified in two main categories: the polyposis syndromes and Lynch syndrome 
(previously known as hereditary nonpolyposis colorectal cancer or HNPCC), respectively. The 
polyposis syndromes are further categorized in familial adenomatous polyposis (FAP), attenuated 
FAP (AFAP), MUTYH-associated polyposis (MAP) and other rare hereditary syndromes such as 
Peutz-Jeghers syndrome, Cowden syndrome and juvenile polyposis or, recently discovered, 
syndromes associated to mutations in DNA polimerases POLE and POLD1(25), (26).  
In 1991, germline mutations in APC were proved to directly cause FAP; FAP patients typically 
develop hundreds to thousands of benign colorectal tumors during their second and third decades of 
life, of which some progress to carcinomas with a high probability (27).  
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Differently from FAP, MAP is an autosomal recessive disease due biallelic mutations in MUTYH 
gene, encoding for a DNA glycolase implicated in the Base Excision Repair system (28). 
Lynch syndrome is characterized by an early onset of CRC at a median age of 42, usually in the 
proximal colon. The defect in Lynch syndrome is an alteration of the above-mentioned DNA 
mismatch repair system (28).   
1.1.4 Colitis-associated Colorectal Cancer (CAC) 
 
Colitis-associated colorectal cancer (CAC) is a subtype of colorectal carcinoma occurring in 
patients with Inflammatory Bowel Disease (IBD), (29). IBD-associated colorectal neoplasia 
accounts for 1-2% of all CRCs, and the importance of this subset of CRC is due to the early age of 
onset (40-50 years), (30). Ulcerative colitis (UC) and Chron's disease (CD), which are the two main 
forms of IBD, confer an increased risk to develop CAC in the successive 20 years after the first 
diagnosis, with a more convincent correlation for UC (31), (32). Although sporadic CRC and CAC 
share several molecular mechanisms and both require accumulation of mutations for cancer 
development, important pathogenic differences discriminate these two types of CRC. Importantly, 
in the case of CAC the classical „'adenoma-carcinoma‟ sequence is substituted by the 
'inflammation-dysplasia-carcinoma' sequence, in which the tumor formation derive from a flat and 
nonpolypoid dysplasia, frequently appearing as a multifocal condition with the involvement of a 
larger area of the colon (31); in this context, the molecular events that underlie the tumorigenesis 
are only in part shared by sporadic CRC and CAC. On an hand, the genomic instability in CIN and 
MSI occurs approximately at the same rate in both types of CRC. Gene silencing by CpG island 
(CGI) hypermethylation also occurs in both sporadic CRC and CAC (33). On the contrary, the 
temporal sequence of genetic mutations results opposite between sporadic CRC and CAC: the loss 
of APC function is usually a rare and a late event in IBD-associated neoplasia intervening in the 
shift from dysplasia to CAC, differently from sporadic CRC (34). Moreover, while p53 alterations 
characterize the final steps of the multistage process of sporadic carcinogenesis, in CAC, p53 
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inactivation occur early and is sometimes observed in absence of dysplasia or in presence of 
indefinite dysplasia, indicating that it can be induced by a chronic inflammatory state preceding the 
onset of CRC (35). Notably, an age-related hypermethylation is found in precancerous colonic 
lesions of patients with IBD, although the global CGI methylation pattern in CAC is also influenced 
by the CIMP status (36). In addition, hypermethylation of hMLH1 promoter gene was detected in 
CAC characterized by a high-frequency MSI (MSI-H) inducing a defective DNA mismatch repair 
system (37). 
 
 
 
Figure 4: Differences in molecular pathways involved in CRC and CAC development, from 
Beaugerie 2015, (38). 
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1.2 Cancer-related inflammation (CRI) 
 
CAC represents one of the clearest evidence of the connection between inflammation and cancer. In 
the case of CAC, the long standing inflammation contributes to the onset of cancer (39). However, 
besides IBD, chronic exposure of intestinal epithelial cells to pro-inflammatory stimuli can be due 
to heterogeneous reasons, including infections (40), microbiota alterations (41), metabolic disorders 
and obesity (42). These evidences suggest that inflammation is implicated in many different 
molecular events, delineating a complicated network linking inflammation to cancer. In this 
context, the role of inflammation is still not fully understood, even if the first characterization of 
leucocytes in tumor samples by Virchow date back more than one century ago (43).  
In sporadic CRC, as well as in the majority of solid tumors, epithelial cells are surrounded by an 
inflammatory microenvironment highly populated by immune cells and rich in  inflammatory 
mediators (44). This inflammatory milieu within the tumor microenvironment  represents the 
“cancer-related inflammation” (CRI) that is now considered one of the hallmarks of cancer (44), 
(45).  
The inflammatory tumor microenvironment is represented by a various mixture of cellular subtypes 
-CD4(+) T-helper 1 (T(H)1) cells, CD8(+) cytotoxic T cells myeloid cells, T regulatory cells 
(Tregs), T-helper interleukin (IL)-17-producing (T(H)17) cells, leukocytes, only to cite some- and 
their products, namely the pro-inflammatory mediators -such as cytokines, chemokines, growth 
factors, proteases and immunosuppressive molecules (29). Notably, the pro-inflammatory mediators 
can be also be produced by the cancer cells in response to the microenvironmental stimulus (Figure 
5) (46),
,
(47): from one part this can represent an ongoing anti-tumor response of the organism, from 
the other part it can be a sign of immune system subversion by the tumor for its  
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Figure 5: The link between cancer and inflammation, from Grivennikov 2010, (48). 
 
own benefit. Indeed, the CRI can play a decisive role not only in the initiation of malignant 
transformation, but also in other mechanisms concerning the tumor progression, such as 
proliferation and survival of malignant cells, angiogenesis, metastasis and subversion of adaptive 
immunity.These mechanisms involve transcription factors such as Nuclear Factor-kappaB (NF-κB) 
and Signal Transducer Activator of Transcription-3 (Stat3), (49) and are driven by different pro-
inflammatory components, such as Interleukin (IL)-1β, IL-6 and Tumor Necrosis Factor (TNF)-α 
(50). It has been demonstrated that the above-mentioned cytokines are able to affect multiple steps 
of the CRI cascade in the context of both CAC and CRC (43). Similarly, Chemokine-8 (CXCL8) 
has been also studied for its primary role in the pathogenesis of sporadic CRC (51)
, 
(52)
, 
(53). In 
particular, one of the proposed mechanisms at the basis of the pro-tumorigenic role of ongoing 
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inflammation is that epithelial cells can produce reactive oxygen and nitrogen intermediates in 
response to the stimulus of the cytokines, which lead to DNA damage and, consequently, gene 
mutations and epigenetic alterations (Figure 6). Moreover, inflammatory mediators downregulate 
DNA repair pathways by a variety of mechanisms, such as the hypoxia inducible factor (HIF)-1α, 
the Activation-Induced Cytidine Deaminase (AID); the doublestrand Break (DSB), or the 
homologous recombination (HR), (44). These mechanisms can converge to the accumulation of 
microsatellite and chromosomal  instabitlity, as shown in Figure 7. 
 
 
 
Figure 6: Molecular pathway involved in inflammation and oncogenesis, from Grivennikov 2010, 
(54). 
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Figure 7: Molecular pathways linking CRI and genetic instability. From Colotta 2009, (44). 
 
 
Due to the complexity of these interconnections, the effects of the combined pro-inflammatory 
mediators, resembling the inflammatory milieu within the tumor microenvironment, in the setting of 
cancer development and progression, particularly in sporadic CRC; have not been completely 
elucidated.  
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1.3 The Notch1 signaling  
 
Notch1 signaling is a highly conserved molecular pathway which controls morphogenesis and organ 
formation in both vertebrate and invertebrates organisms (55), (56). Notch1 pathway can drive a 
surprisingly wide spectrum of specific functions, such as differentiation, proliferation and apoptosis, 
which are able to influence cell fate and to regulate the homeostasis of tissues (57). Due to its 
fundamental function, the involvement of deregulated Notch1 signaling in many pathological 
processes is understandable (58), as well as the possibility of considering it as a common cause for 
different types of tumors (59). 
Although the functions mediated by the Notch1 signaling can be extremely complex, most of the 
Notch1-dependent processes are based on the same molecular mechanism, grounded on a direct 
cell-cell model of communication (60). 
In humans, the core components of this pathway includes four distinct Notch1 receptors (Notch1-4) 
and their ligands (Jagged1, Jagged2, DLL1, DLL3 and DLL4). Both Notch1 receptors and ligands 
are single-pass trans-membrane proteins with extracellular domains characterized by multiple 
epidermal growth factor (EGF)-motifs. (49), (Figure 8). 
The Notch1 receptors arise from a larger precursor of 300 KDa which need to be further processed 
in order to obtain the mature form. The first post-translational modification occurs in the 
endoplasmic reticulum and depends on the enzymatic activity of O-fucosyltransferase 1 (Ofut1); 
(61). Subsequently, the furin-like convertase enzyme carries out the cleavage of the glycosylated 
precursor in the Golgi, generating the N-terminal extracellular domain of Notch1 (NECD) and the 
transmembrane-Notch1 intracellular domain (NICD), which together constitute the mature receptor. 
This complex is further glycosylated during the passage through the Golgi by Fringe 
glycosyltransferase enzymes. Then, Notch1 mature receptors are translocated on the cellular 
membrane (62).  
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Figure 8: The Notch1 receptors and Ligands, modified from Andersson 2011, (58). 
The physical interaction of Notch1 receptors with one of the specific ligands activates the signaling 
and Notch1 receptors undergo subsequent proteolytic cleavages. The first proteolityc event is 
catalyzed by the TACE metalloproteinase (ADAM17) and induces the cleavage of the extracellular 
portion of the receptor (NECD) which is subsequently internalized through endocytosis (63). The 
remaining anchored part of the receptor is further processed by the γ-secretase enzyme releasing the 
active intracellular domain of Notch1 (NICD).  
In the canonical Notch1 signaling, NICD translocates into the nucleus where interacts with the 
transcriptional repressor protein CSL/RBP-J. Following the recruitment of co-activators 
Mastermind-like (MAML) and the histone acetyltransferase (HAT) p300, CSL/RBP-J is converted 
into a transcriptional activator, inducing the transcription of downstream target genes including 
Hes1 and c-Myc  (64), (Figure 9).  
Importantly, recent literature acknowledges an RBP-Jκ-independent activation of the Notch1 
pathway, able to participate in several cellular processes, which is defined the “non-canonical 
Notch1 pathway” (65). In particular, a role for non-canonical Notch1 signaling in oncogenesis has 
been suggested by the evidence that inhibition of γ-secretase does not block all Notch1-related 
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functions in tumor cells (66). The mechanisms able to interact in a non-canonical manner with 
Notch1 are involved in the regulation of the Wnt signaling pathway, affecting the stability of β-
catenin (67) , as well as in the response to inflammation, as reported below. 
 
 
Figure 9: The Notch1 pathway. From Bray 2006, (56). 
 
1.3.1 Notch1 signaling in CRC 
 
In physiological conditions, Notch1 signaling is crucial for the maintenance of stem cell phenotype 
as well as for the regulation of cell fate in the intestinal tissue (68). However, it is well known that 
the deregulation of the Notch1 signaling cascade plays a pivotal role in several solid tumors, 
including CRC (69).  
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Importantly, while DLL1-mediated Notch1 signaling is required for intestinal stem-cell homeostasis 
(70), the binding to Jagged1 is associated with colon carcinogenesis (71). It has been recently 
demonstrated that besides the classical downstream target HES1, which in turn blocks atonal 
homolog 1 (ATOH1) transcription, in the gut epithelium the Notch1-regulated ankyrin repeat 
protein (NRARP) transcription level accurately reveals the intestinal activation of Notch1 (72).  
Depending on the CRC setting, a dichotomy for the role of Notch1 pathway activation has been 
reported: while in sporadic or hereditary models of CRC Notch1 seems to act as an oncogene and is 
required for adenoma formation (73) and cancer progression (74), in CAC Notch1 seems to have a 
tumor suppressor role and its inhibition is associated with increased apoptosis (75). The tumor-
suppressor role of Notch1 in the development of CRC has been strongly demonstrated by Kim and 
colleagues, which showed that the induced activation of Notch1 in a transgenic murine model of 
FAP (ApcMin/+  mouse model) converted intestinal high-grade adenoma into low-grade adenoma 
(72).  
1.3.2 Notch1 signaling and inflammation 
 
Recent experimental results acknowledge the role of the Notch1 pathway for regulating 
inflammatory processes (76). Moreover, different pathways, involved in the response to 
inflammation, are able to modulate the non-canonical Notch1 pathway, such as the nuclear factor 
kappa-light-chain-enhancer of activated B cells (NFkB) (77), the pathway of hypoxia-inducible 
factor 1 alpha (HIF- 1α) (78), the epithelial-to-mesenchymal transition (EMT), (79), (80), which is 
discussed below, the Wnt signaling (67) or the mitogen-activated protein kinase (MAPK) and 
nutrient sensor kinase mTOR (81), only to cite some. 
In CRC, the activation of Notch1 signaling in response to pro-inflammatory stimuli has recently 
emerged (82). Taniguchi and colleagues showed that gp130, a co-receptor for IL-6, triggers 
activation of Yes-associated protein (YAP) and Notch1, independently of the classic gp130 effector 
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STAT3, leading to the proliferation of epithelial cell (83). Also,  the protective role of Notch1 
activation in the context of CAC tumorigenesis  regards the role of Matrix Metalloproteinases-9 
(MMP9), a protein involved in the epithelial to mesenchymal transition. Indeed, Garg and 
colleagues demonstrated that  MMP9, despite notoriously being a pro-inflammatory mediator, plays 
a protective role by modulating Notch1 and β-catenin through p21 expression in a model of CAC 
(80). At the same time, it has been also demonstrated  that MMP9 is able to induce an oncogenic 
activation of Notch1 signaling pathway in an inflammation-related context; indeed, Pope and his 
group recently found that the up-regulation of Claudin-1, an integral component of the tight 
junctions structure, causes the activation of Notch1-signaling through  MMP9 and p-ERK, thus 
increasing the susceptibility to mucosal inflammation (84). Moreover, Lin J and colleagues sustain 
the role of inflammatory factors in promoting Notch1 pathway activation and colon cancer 
progression, for example through the axis IL-6/Notch1 (82).  
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1.4 Epithelial to Mesenchymal Transition (EMT) 
Epithelial to mesenchymal transition (EMT) is a functional process recognized as a central feature 
of normal development. Several processes involved in embryogenesis, such as gastrulation, neural 
crest formation and heart morphogenesis, are grounded on the plastic transition between epithelium 
and mesenchyme (85). Through the EMT program, a polarized epithelial cell, normally interacting 
with the basement membrane via its basal surface, is subjected to various biochemical changes and 
acquires augmented migratory capacity, elevated resistance to apoptosis and  increased production 
of extracellular matrix (ECM) components, globally assuming a mesenchymal phenotype (Figure 
10), (86).  
 
Figure 10: The epithelial to mesenchymal transition. From Lamouille 2014, (87). 
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Several molecular features characterized the EMT process, as summarized in Figure 11 (87). 
During EMT, E-cadherin (encoded by CDH1 gene), a cell adhesion molecule of the membrane of 
most normal epithelial cells, is repressed or degraded. A variety of signal transduction pathways 
participate to the regulation of E-cadherin, among these SNAIL is known to repress CDH1(88). The 
family of SNAIL proteins (SNAIL1 and SNAIL2/SLUG) plays an important role during EMT: its 
function is to repress epithelial genes by binding to E-box DNA sequences through their carboxy-
terminal zinc-finger domains (89). Then, homodimeric and heterodimeric basic helix–loop–helix 
(bHLH) transcription factors function as master regulators of lineage specification and 
differentiation. In particular, E12 and E47, TWIST1 and TWIST2 have key roles in EMT 
progression; the ZEB transcription factors (ZEB1 and ZEB2) also bind regulatory gene sequences at 
E-boxes and can modulate transcription (90). Notably, changes to the integrins during EMT also 
induces the expression of proteases, in particular of the matrix metalloproteinases (MMP) 2 and 9; 
this event leads to the degradation of the components of ECM protein and, subsequently, to an 
increased invasiveness. Moreover, MMPs are able to modulate the expression of specific 
transmembrane proteins involved  in the release of the extracellular domain of E-cadherin, an event 
related to the loss of adherens junctions (91). 
Besides these “classically” recognized master regulators of EMT, it has been recently demonstrated 
that many other signaling networks are involved in this process, such as miRNAs, TGFβ family 
proteins, the tyrosine kinase receptors, the insulin-like growth factor 1, only to cite some (87). Of 
particular interest for the present study is the evidence that Notch1, as well as inflammatory 
mediators, contribute to the induction of EMT. For instance, it has been reported that Notch1 
signaling is required for EMT during endocardial cushion formation, and reduced SNAIL1 occurs 
in Notch1-deficient mice
 
(92). Also, the release of IL-6 promotes EMT of breast cancer cells in 
culture, which correlates with a decrease in E-cadherin levels, an increase in SNAIL1 and TWIST 
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levels, leading to augmented cell invasion (93). Similarly, it has been demonstrated that the 
promotion of the EMT correlates with the increased secretion of IL-8 in tumor cells, and this latter 
in turn maintains the mesenchymal phenotype of  the cells (94). 
 
Figure 11: Transcriptional factors involved in EMT. From Lamouille 2014, (87). 
1.4.1 Epithelial to Mesenchymal Transition in CRC  
EMT has been well documented in multiple cancer models, including CRC (95). During 
tumorigenesis, EMT increases the motility and invasiveness of cancer cells; in parallel, malignant 
transformation may be associated with signaling pathways promoting EMT (96), (97). Various 
processes associated with EMT occur during tumor progression, and these processes closely 
resemble those occurring in normal development. In this context, it is believable that a possible link 
between Notch1 signaling, inflammation and MMP9 could exist, even if the relationship among 
them remains unclear. 
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1.5 Polyunsaturated Fatty Acids (PUFAs)  
The omega-3 Polyunsaturated Fatty Acids (ω-3 PUFAs) are carboxylic acids consisting of a long 
hydrocarbon chain with a carboxylic (-COOH) and a methyl group (-CH3) located at the ends of the 
molecule. The nomenclature “ω-n” indicates the presence of double bonds at the n carbon of the 
hydrocarbon chain from the methyl group (Figure12).  
Given their importance for human health ω-3 PUFAs are classified as essential fatty acids (98). 
Moreover, the ω-3 PUFAs are considered crucial dietary components because humans are not able 
to synthesize them from the precursor alpha-linolenic acid (ALA), despite they are fundamental 
constituents of cellular membranes. The ω-3 PUFAs include two subtypes of molecules: 
Eicosapentaenoic acid (EPA) and Docosahexaenoic Acid (DHA). EPA and DHA are present in 
fishes fed with algae (tuna, salmon, mackerel or sardines), able to produce them as result of their 
metabolism; however, a modest amount of PUFAs is also contained in plants (linseed, primrose, 
echium) but the bioavailability in this case is lower than the content in Fish Oil (FO), (99). 
 
Figure 12: Structure of the Polyunsaturated fatty acids, from Rennison 2009 (100). 
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The healthy benefits  related to the consumption of ω-3 PUFAs are largely proved by scientific 
literature: epidemiological studies began in 1970s and showed that the Greenland Eskimos had low 
mortality rates due to coronary heart disease because of their high consumption of ω-3 FO fatty 
acids. These epidemiological associations led to evaluate the preventive effects of FO against 
cardiovascular diseases (CVDs) as well as against  inflammatory-related disease and, more recently, 
also against cancer (101) . 
1.5.1 Anti-inflammatory properties of omega-3 PUFAs  
 
Many data have been collected on the anti-inflammatory activity of EPA and DHA (102).  
One of the key mechanisms of ω-3 PUFAs anti-inflammatory activity is the inhibition of COX-2- 
dependent synthesis of prostaglandins (PGs), through the replacement of Arachidonic acid –which 
is  the substrate for the synthesis of the pro-inflammatory PGE2- from the cellular membrane by the 
ω-3 PUFAs. Therefore, by acting as an alternative substrate for COX-2, EPA and DHA lead to a 
reduction of PGE2 formation favoring the PGE3 series, which have anti-tumorigenic activity (103).  
EPA is also able to generate oxygenated compounds such as Resolvins (Rvs), which are anti- 
inflammatory lipid mediators (104):  in Fat-1 transgenic mice, which are able to convert 
endogenous ω-6 to ω-3 PUFAs, an increased tissue level of ω-3 led to a significant release of 
resolvins, with an effective reduction of inflammation and tissue injury in chemically induced 
colitis (105).  
Moreover, ω-3 PUFAs are important modulator of the immune response. McMurray and colleagues  
showed that the PUFAs present in fish oil affects CD4+ T cell proliferation and cytokine production 
in C57BL/6 mice through the indirect suppression of T helper (Th) 1 cells by cross-regulation of 
enhanced Th2 activation (106).  
A further mechanism of action, particularly related to EPA action, could be exerted by the direct 
binding with G protein coupled receptors (GPRs), among which GPR120, a receptor present on the 
membrane of macrophages. Indeed, in the monocytic RAW264.7 cells and in primary 
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intraperitoneal macrophages, treatment with ω-3 PUFAs inhibited inflammation and enhanced 
systemic insulin sensitivity through GPR120 (107). 
Nevertheless, the incorporation of EPA and DHA into the phospholipidic bilayer induces changes in  
the composition of the cellular membrane in terms of structure, fluidity and function of caveolae. 
Indeed, ω-3 PUFAs enrichment selectively modifies the cytoplasmic layer of detergent-resistant 
membrane domains, acting as functional rafts within the plasma membrane bilayer: this alteration 
could underlie the inhibition of T cell signal transduction (108). 
1.5.2 Anti-neoplastic properties of omega-3 PUFAs on CRC  
 
The beneficial effects of ω-3 PUFAs against CRC have been widely observed in many in vitro and 
vivo studies (109), (110), (111), (112).  
Recently, our group found that a pure preparation of Eicosapentaenoic Acid as free fatty acid (EPA-
FFA) led to a dramatic suppression of polyp number, load and size in the ApcMin/+ mouse model. 
Importantly, EPA-FFA fed animals displayed a significant reduction of COX-2 and nuclear -
catenin expression, and a significant decrease of lipid peroxidation (113). 
We also demonstrated the effectiveness of substituting EPA-FFA for other dietary fats, in 
preventing inflammation and cancer in the AOM-DSS model of CAC. We found that EPA-FFA diet 
strongly decreased multiplicity, incidence and maximum size of tumor. Moreover EPA-FFA 
reduced cell proliferation and nuclear β-catenin expression and increased apoptosis. EPA-FFA 
treatment led to increased membrane switch from ω-6 to ω-3 PUFAs and a concomitant reduction 
in PGE2 production. Importantly, we found that EPA-FFA treatment restored the loss of Notch1 
signaling found in the AOM-DSS control and resulted in the enrichment of Lactobacillus in the 
microbiota. These data suggest that EPA-FFA is an effective chemopreventive agent in CAC (114). 
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2. AIM OF THE WORK  
Our group has recently demonstrated that an extra-pure formulation of Eicosapentaenoic Acid as 
Free Fatty Acid (EPA-FFA) is able to prevent cancer development both in the ApcMin/+ mouse 
model of FAP and in the AOM/DSS mouse model of colitis-associated cancer (CAC). However, the 
molecular mechanisms which underlie the chemopreventive role of EPA-FFA are poorly 
understood. Therefore, the aims of this study were: 
- To re-create an in vitro model of interaction between a heterogeneous mix of 
proinflammatory mediators and CRC cells; 
- To determine whether the Notch1 signaling is  induced in this model and if this mechanism 
could be related to EMT in CRC cells; 
- To investigate whether this pathway can be counteracted by the treatment with EPA in a 
free-fatty acid form (EPA-FFA).  
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3. MATERIALS & METHODS  
 
3.1 Cell lines and treatments 
 
The human colorectal cancer cell lines HT29 and  HCT116, which represent two different 
molecular models of CRC, and the human monocyte cell line THP-1 were obtained from ATCC 
(Manassas, VA, USA; catalog numbers ATCC-HTB-38
TM
, ATCC-CL-188
TM
, ATCC-TIB-202
TM
, 
respectively). In our laboratory, all cell lines are tested and authenticated every year using known 
genetic and epigenetic markers. 
3.1.1 Cell lines Culture 
 
HT29, HT29 Notch
-/-
, HT29-MMP9
-/-
 and THP-1 cell lines were cultured in Roswell Park 
Memorial Institute (RPMI)-1640 (with the addition of 50µM of β-mercaptoethanol for THP-1 and 2 
µg/ml of puromycin for HT29 Notch
-/-
), while HCT116 cell line was grown in Iscove‟s Modified 
Dulbecco Media (IMDM). The culture media were supplemented with 10% FBS (20% for THP-1), 
100 U/ml penicillin, 100 µg/ml streptomycin and 2mM glutamine (Euroclone, Milan, Italy). The 
cells were maintained at 37°C and 5% CO2.  
3.1.2 Treatment with Eicosapentaenoic Acid, free fatty acid (EPA-FFA) 
 
Eicosapentaenoic acid as the free fatty acid (EPA-FFA, ALFA, SLA Pharma AG, Switzerland) was 
diluted 1:100 in EtOH 95% prior to use. This preparation was done freshly for every experiment 
protecting from light. EPA-FFA was used for cell culture treatments both at 72h and 14 days at the 
concentration of 50 µM. Every experiment was repeated at least three times. 
3.1.3Treatment with Conditioned Medium (CM) or single pro-inflammatory mediators 
 
HT29, HCT116 and LS174T cell lines were exposed to CM for 12h. In the case of EPA-FFA 
treated cells, after incubation with EPA-FFA for 72h the cells were washed with PBS and incubated 
with CM. HT29 cells were also incubated with 100 ng/ml of interleukin-6 (IL-6, Immunological 
Sciences, Roma, Italy), 1µg/ml of chemokine-8 (CXCL8, Sigma Aldrich) or 100 ng/ml of Tumor 
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Necrosis Factor-alpha (TNF-α, PeproTech Inc., Rocky Hill, United States), or their combination for 
72h. Every experiment was repeated at least three times. 
3.2 Conditioned Medium (CM) production and characterization 
 
3.2.1 Conditioned Medium (CM) production 
 
THP-1 cells were differentiated into macrophages using 5 ng/ml of phorbol 12-myristate 13-acetate 
(PMA, Sigma Aldrich, Milan, Italy) for 72h. After differentiation, the medium containing PMA was 
removed,THP-1 were washed with PBS and incubated in RPMI supplemented with 50 ng/ml of 
E.coli lipopolysaccharide (LPS, strain 055:B5, Sigma Aldrich) for 1h. Then, the medium containing 
LPS was replaced with fresh medium in order to obtain an LPS-free, cytokine-enriched conditioned 
medium (CM), (115), (116). After 24h, the CM was collected, filtered and stored at -80°C until use.  
3.2.2 Fluorescence Activated Cell Sorting (FACS) analyses 
 
The differentiation of THP1 into macrophages was assessed by determining the CD14 and CD11b 
positive cell population. Briefly, 0.5x10
6
 PMA-treated THP-1 cells were washed with PBS and 
suspended in 100ul of PBS supplemented with 1 % of Bovine Serum Albumin (BSA). Then, the 
samples were incubated with PerCP-conjugated anti-CD14 (Miltenyi Biotec, Bologna, Italy) alone, 
PE-conjugated anti-CD11b (Exalpha Biologicals, MA, U.S.A.) alone and with the combination of 
both antibodies on ice for 30 minutes. After antibody incubation, the cells were washed twice in 1 
ml of PBS supplemented with 1 % BSA and resuspended in 300ul of PBS supplemented with 1 % 
BSA for further analysis with a FACSaria flow cytometer (BD Biosciences, Milano, Italy). 
Unstained cells were used as negative control. Data were analysed using BD FACSDiva software. 
The experiment was repeated at least twice. 
3.2.3 Cytokine analysis 
 
The CM composition was characterized by measuring the concentrations of the major cytokines: 
interleukin (IL)-1β, IL-2, IL-4, IL-6,  CXCL8, IL-10, IL-12, IL-17, interferon-γ (IFNγ), monocyte 
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chemoattractant protein-1 (MCP-1), macrophage inflammatory protein 1-β (MIP1-β), tumor 
necrosis factor-α (TNFα), granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage 
colony-stimulating factor (GM-CSF) with a multiplex bead-based sandwich immunoassay (Bio-
Plex, Bio-Rad Laboratories, Milan, Italy). This system relies on the emission of fluorescence 
resulting from the binding of a biotinylated antibody with a  complex constituted by an antibody-
coupled fluorescent dye bead and a specific cytokine. The reaction is revealed using streptavidin-
phycoerythrin (streptavidin-PE), which binds to the biotinylated detection antibody. The Bio-Plex 
Manager™ software automatically calculates cytokines concentrations in the sample using a 
standard curve derived from a recombinant cytokine standard. The use of the different colour beads-
set allows the discrimination and simultaneous quantification of multiple cytokines in the same 
sample. CM samples were also diluted with the specific Bio-Plex human sample diluent (1:10). 50 
μl of cytokine standards or samples were added to each well of a 96-well plate and incubated with 
50 μl of coupled beads for 30 minutes at room temperature under shaking conditions (850 rpm). 
Plates were then washed by vacuum filtration with 100 μl of Bio-Plex wash buffer three times, then 
25 μl of diluted detection biotinylated antibody were added and plates were incubated for 30 
minutes at room temperature undershaking conditions. After three filter washes, 50 μl of 
streptavidin-PE were added, and the plates were incubated for 10 minutes at room temperature 
under shaking conditions. Finally, plates were washed by vacuum filtration three times, beads were 
suspended in Bio-Plex assay buffer, and samples were analyzed on a Bio-Rad 96-well plate reader 
using the Bio-Plex Suspension Array System and Bio-Plex Manager software (Bio-Rad 
Laboratories, Hercules, CA). For each condition, two CM from different experiments were tested. 
Each sample was tested in duplicate, and cytokine standards supplied by the manufacturer were run 
on each plate. 
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3.3 Protein expression analysis  
 
3.3.1 Protein extraction 
 
Proteins were extracted from cultured cells with  RIPA buffer (50 mM Tris-HCl-pH 7.4, 150 mM 
NaCl, 1% NP-40, Proteases and Phophatases inhibitors) and the total protein concentration was 
measured using the Lowry assay(Bio-Rad Laboratories), a colorimetric technique which allows to 
estimate the amount of proteins in biological samples. 
First, proteins diluted tenfold in water were pre-treated with copper ion in alkalin solution for 20 
minutes; then the aromatic amino acids in the treated sample reduced the acid present in the Folin 
Reagent further added. The final product of this reaction has a blue colour;  the amount of proteins 
in the sample has been estimated reading the absorbance at 750 nm with a spectrophotometer 
(BIOMATE, ThermoSpectronic, MI, Italy) using a standard curve of a selected standard protein 
solution (in our case BSA solution).  
3.3.2 Western Blotting 
 
Eighty μg of proteins for each sample were separated on a 4-12% SDS-polyacrylamide gel (Life 
Technologies, Monza, Italy) and transferred o.n. onto nitrocellulose membrane. After being blocked 
with non-fat dry milk, the membranes were incubated overnight at +4°C with the following primary 
antibodies: mouse monoclonal anti-Notch1 1:1000 (clone mN1A, catalog number 629101, 
Biolegend, SA, USA), rabbit polyclonal anti-cleaved Notch1 1:500 (Val1744, catalog number 2421, 
Cell Signaling Technologies, Leiden, Netherlands), rabbit polyclonal anti-JAG1 1:200 (clone H-
114, catalog number sc-8303, Santa Cruz Biotechnology, Heidelberg, Germany), rabbit monoclonal 
anti-ZEB1 (anti-TCF8/ZEB1, 1:1000, clone: D80D3, Cell Signaling), rabbit polyclonal anti-MMP9 
(1:1000, catalog number: 3852, Cell Signaling), and rabbit monoclonal anti-CDH1 (1:1000, clone: 
24E10, catalog number: 3852, Cell Signaling). Following incubation with the appropriate secondary 
antibody, the signal was detected with Chemiluminescent Sensitive Plus HRP (BioFx Laboratories, 
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MD, United States), and images were acquired with the ChemidocTM XRS+ (Bio-Rad 
Laboratories). For housekeeping protein, mouse monoclonal anti-β-actin (1:2000, clone AC-15, 
catalog number A1978, Sigma Aldrich) was used. Each experiment was repeated at least twice. 
3.4 Gene expression analysis 
 
3.4.1 RNA extraction and retro-transcription 
 
Total RNA was extracted from cells using Trizol® Reagent (Life Technologies, Monza, Italy) 
following the manufacturer's instructions. RNA concentration was evaluated by measuring the 
absorbance (optical density, OD) at 260 nm; protein and ethanol contamination were evaluated 
dividing the absorbance at 260 nm for the absorbance at 280 nm (OD 260/280) or 230 nm (OD 
260/230), respectively. All measurements were performed using NanoDrop spectrophotometer 
(Thermo Scientific).  
One μg of total RNA was reverse transcribed using GoScriptTM Reverse Transcriptase Kit 
(Promega, Milan, Italy). Briefly, RNA and Oligo(dT)15 primers were heated at 70°C for 5 minutes 
followed by a step on ice for 5 minutes, then the reverse transcription mix added to the 
primers/RNA mix in a final volume of 20 μl. The reverse transcription mix was composed of 4.0 μl 
of GoScript™ reaction buffer, 4.0 μl of MgCl2 25 mM, 1.0 μl of nucleotide mix 10mM, 0.5 μl of 
Recombinant RNasin® Ribonuclease Inhibitor (40 U/ μl), 1.0 μl of GoScript™ Reverse 
Transcriptase and 4.5 μl of nuclease free water. After annealing at 25°C for 5 minutes, the extension 
reaction was performed at 42°C for 60 minutes and reverse transcriptase was then inactivated at 
70°C for 15 minutes. The obtained cDNA was diluited 1:10 with MilliQ water and stored at -20°C 
until  use. 
3.4.2 qRT-PCR: Gene Expression Assay  
 
qRT-PCR was performed using TaqMan Gene Expression Assays for HES1 (Hs00172878_m1), 
ATOH1 (Hs0094192_s1), GAPDH (Hs99999905_m1) or Sybr select Master mix for JAG1, NRARP, 
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ZEB1, MMP9 and CDH1 (Life Technologies). Primer sequences for Sybr green assays are reported 
in Table 1. qRT-PCR was performed on iCycler (Bio-Rad Laboratories)  
The thermal profile for Sybr select Master mix reactions was: 50°C for 2minutes, 95°C for 
2minutes, (95° for 15seconds, 53°C for 15seconds, 72°C for 30seconds) x 40 cycles, 45°C for 
10seconds. The thermal profile for TaqMan Gene Expression reactions was: 95°C for 10minutes, 
(95°C for 15seconds, 60°C for 15seconds) x  40 cycles, 4°C-hold. 
Fold induction levels for each gene were analysed by means of the 2
-∆∆Ct
 method, and GAPDH was 
used as endogenous control. At least two replicates were analysed for each sample.  
 
Table 1: Primer Sequence for qRT-PCR 
 
3.5 Gene silencing 
 
3.5.1 Notch1 stable silencing 
 
Short hairpin oligonucleotides (shOligos) complementary to shRNA sequences were inserted into 
the pSuper.puro expression vector according to the manufacturer‟s instructions (OligoEngine, 
Seattle, WA), (117). ShOligos targeting different Notch1 exons were as follows: Notch1 (N1S), 5′-
ggccgtcatctccgacttca-3′; and Notch1 (N1S1), 5′-gcctcttcgacggctttga-3′. Retroviruses were produced 
by transient transfection of pSuper.puro retrovectors into Phoenix A packaging cells (kindly 
provided by Dr Catia Giovannini).  
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Stable, retroviral transduced populations of cells HT29 NOTCH1
-/-
 were selected in RPMI 
supplemented with 2µg/ml of puromycin, as previously established by the killing curve. 
3.5.2 Metalloproteinase-9 (MMP9) transient silencing  
 
HT29 cells were transfected for 48h with 50nM of a mixture of 4 small interfering RNA (siRNA) 
against MMP9 (ON-TARGETplus SMARTpool siRNA sequences,Dharmacon, Thermo Fisher 
Scientific, Cultek SL, Madrid, Spain), using Dharmafect transfection reagent-1 (Thermo Fisher 
Scientific, T-2001-01). A non-targeting siRNA (D-001810-10-05, Dharmacon) was used as a 
negative control (scramble). 
3.6 Cell viability assay 
 
Cell sensitivity to EPA-FFA was evaluated by the 3-(4,5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide assay (MTT, Sigma Aldrich) assay. This colorimetric assay is a 
reliable way to examine cell viability since this latter is directly proportional to the metabolic 
activity of the mitochondria. Indeed, MTT is a water-soluble tetrazolium salt metabolized only by 
living cells and converted into formazan by the action of a dehydrogenase enzyme. The formazan is 
violet and appears as insoluble material at the bottom of the culture plate. The formazan is 
solubilized in DMSO to form a purple solution whose intensity is proportional to cell density.  
HT29 and HCT116 cells were seeded in 96-well plates at a density of 5 and 3x10
3 
cells, 
respectively, and incubated for 72 h prior to treatment with EPA-FFA (0-200µM). Following 
treatment, the medium was removed and the cells were washed with PBS.Then, MTT (5 mg/mL) 
was added and the cells were incubated at 37°C for 4h. After the incubation, the medium was 
discarded and 100uL of solubilization reagent (10% SDS in HCl 0.01N) was added in each well. 
Then, the formazan formed was dissolved in DMSO (200μl) andthe day after, the absorbance at 560 
nm was measured in a microplate reader (GloMaxÂ®-Multi Microplate Reader (Promega 
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Corporation, Madison, WI, USA) The absorbance values were expressed as percentage of control 
(untreated cells). Each experiment was performed in quintuplicate. 
3.7 Mucosal fatty acid analysis  
 
In order to examine the relative content of EPA into the cellular membranes of control and treated 
cells, the whole amount of lipids was extracted from the cells, chemically treated -as reported 
below- and the content was analyzed by Gas Cromatography-Mass Spectrometry (GC-MS). 
3.7.1 Lipid extraction  
 
The cellular pellets were resuspended in ice-cold PBS and transferred with Pasteur pipettes in 
Sovirel extraction tubes, washed with 3 ml of chloroform-methanol mixture (CHCl3/MetOH 1:2 
vol/vol) in presence of the antioxidant butylated hydroxytoluene (BHT 0.01%) and shaked for 30 
minutes at room temperature.Then, samples were centrifuged for 10 minutes at 2000 x G at room 
temperature and the upper solvent layer was transferred in a new Sovirel tube. The extraction was 
repeated with 2 ml of solvent and the supernatant layer combined. The solvent fraction was then re-
extracted with 3 ml of CHCl3/H2O (1:1 - BHT 0.01%), vortexed and spinned, (2000 x G, 5 min, 
25°C); the inferior solvent phase was transferred to a new Sovirel tube and frozen at –20°C untilthe 
transesterification. 
3.7.2 Transesterification  
 
The solvent phase was evaporated under a stream of nitrogen and 2 ml of KOH/MetOH solution 
(0.5M + 0.01% BHT) were added, the tubes carefully closed and heated at +80°C for 10 minutes in 
a dry thermal block. When the temperature of the solution reached 25°C 1 ml of BF3: MetOH 
solution was added to each sample and the tubes were warmed at +80°C in the thermal block for 10 
minutes to develop a methyl ester mix. 
3.7.3 Extraction of methyl esters 
 
Methyl esters were extracted adding 3 ml of hexane to each sample. The samples were then 
vortexed for 30 seconds and spinned at 2000xG for 10 minutes at room temperature. The 
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supernatant solvent phase was carefully recovered and transferred to a new glass tube. This 
extraction process was repeated with 2 ml of hexane. Then, the hexane was evaporated under a 
stream of nitrogen to reduce the volume to 1 ml which was then transferred to a glass auto sampler 
vial. The tube was washed with 500 μl of hexane and the sample evaporated to dryness, redissolved 
with 20 μl of ciclohexane for the analysis and frozen at –20°C until injected. 
3.7.4 Gas Cromatography-Mass Spectrometry (GC-MS) conditions 
 
GC-MS analysis was carried out using an Agilent HP6890 GC with PTV Injector and MS with 
aHP5973 mass detector; The column is SUPELCO SPTM-2330 (30mt x 0.25 mm x 0.2 μm film 
thickness) column. Carrier gas is Helium at 0.5 ml/minutes, in constant pressure mode; Injection 
cycle is in Solvent Vent mode, starting from 60° and ramps to 220°C; column temperature was from 
100°C for 1.25 minutes, then was programmed to rise to 185°C at 30 °C and to 205°C at 5 
°C/minutes; total GC run time was 32 minutes 1-4 μl samples was injected to GC-MS analysis. MS 
operates in EI mode, at 70 eV; Quadrupole temperature is 150°C; Ion source and GC interface were 
respectively 230°C, 280°C; Full data scan from m/z 40 to m/z 550. 
3.7.5 Data processing and quantification 
 
Retention times and peak area of analytes were determined by the Enhanced Data Analysis 
integration system of G1701 DA Agilent software. The percentage of analytes was calculated from 
the sum of the peak area of all analytes of interest using the following equation: 
 
                                                      Analyte Peak area * 100  
Analyte percentage =      _______________________________  
                                             
                                                  (Σ areas of all identified peaks)  
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3.8 Invasion assay 
 
The invasive potential of HT29 and HCT116 cells was assessed by chemoinvasion assay (118).  
Briefly, poly-vinylpyrrolidone-free polycarbonate filters (Millipore, Co. Cork, Ireland) with 8 µm 
pores were coated with Matrigel (Sigma-Aldrich) and positioned in the middle part of the Boyden 
blind-well chambers (New Technologies Group, Monza e Brianza, Italy). Fresh RPMI 
supplemented with 20% FBS was placed in the lower part of the chamber as chemoattractant. After 
CM and/or EPA-FFA treatment, 7×10
4
 HT29 and HCT116 cells were resuspended in serum-free 
medium and added to the upper part of the chambers. The chambers were then incubated at 37°C in 
humidified 5% CO2. At the end of incubation, non invading cells were removed from the upper 
surface of the filters with cotton swabs. Invading cells in the lower surface were then fixed for 1 
minutes in ethanol 95% and stained for 10 min with 0.5% w/v with Giemsa (Sigma Aldrich). 
Photographs were taken with an Olympus CKX41 inverted microscope (Olympus Italia, Milan, 
Italy), equipped with an Olympus C5060-ADU camera (Olympus Italia). For each sample, ten 
random optical fields at ×200 of total magnification were analyzed and the mean number of 
invading cells was counted. 
 
3.9 Gelatin Zymography 
 
MMP9 activity was determined by gelatin zymography as previously described (119) with minor 
modifications. Cells were treated with CM for 12h, then CM was removed and cells were incubated 
o.n. in serum-free medium. The media was collected, centrifuged (400g, 5minutes at 4°C) to 
remove cells and debris, and precipitated using three volumes of Methanol at -20°C o.n. Proteins 
were precipitated with 1:4 (vol/vol) ice-cold methanol o.n. Proteins were pelleted by centrifugation 
at 6500G at 4°C for 40 minutes and the pellets were resuspended in PBS. Protein concentration was 
determined using Lowry‟s assay. After solubilization with sample buffer (not containing reducing 
agents, but only SDS at 8% to charge proteins-Tris HCl pH6.8, SDS 8%, Glycerol 40%, 
Bromophenol blue 0,4%), 20 μg of proteins were loaded in 10% polyacrylamide gels, previously 
46 
 
co-polymerized with 1% gelatin. After electrophoresis, the gels were washed twice in 2.5% in H20 
Triton X-100 and incubated o.n. in an activation buffer (50 mM Tris–HCl supplemented with 5 mM 
CaCl2). The digested bands on the gels were highlighted  with Comassie brilliant blue R-250 
staining and de-stained with 50% methanol and 10% acetic acid in distilled water. MMP9 
proteolytic activity was quantified using ChemiDocTM XRS+(Biorad, CA, USA).  
3.10 Statistical analysis 
 
Data were analyzed with Graphpad 5.0 Software (GraphPad Software Inc., CA, USA). Whenever 
necessary, the values were transformed using the function Y=log(Y) to stabilize the variances. The 
means of two unmatched groups were compared using the unpaired T test, while the one-way 
ANOVA followed by Tukey‟s or Dunnet‟s post hoc tests were used to compare the means of three 
or more groups. The data are shown as Mean±SEM. P values less than 0.05 were regarded as 
statistically significant. 
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4. RESULTS 
 
4.1 Conditioned Medium production 
 
First, we differentiated the THP1-monocytes into macrophages using PMA and we stimulated them 
with LPS; then, we collected the cytokine-enriched supernatant. Through this approach we obtained 
a complex and heterogeneous stimulus able to mimic of the pro-inflammatory microenvironment. 
4.1.1 Differentiation of THP1 from monocyte to macrophages 
 
It is known that monocytes are highly plastic and heterogeneous, and that they are able to change 
their functional phenotype. Evidences from  murine and human studies have suggested that they can 
differentiate into tissue macrophages in response to environmental stimulation. Also, based on 
specific markers of cellular surface, it is possible to identify the specific subset of differentiated-
cells (120). 
FACS analysis of PMA-differentiated THP1 cells showed increased expression of specific markers 
of macrophages, namely CD11b (p=0.0027) and CD14 (p=0.0507), compared to untreated THP1, as 
shown in Figure 13. 
 
Figure 13: FACS analysis for the expression of CD11b and CD14 in THP1 cells untreated (CTRL) 
or treated with PMA. 
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4.1.2 Stimulation of THP1induced the release of pro-inflammatory mediators 
 
Macrophages play a key role in the orchestration and execution of the inflammatory processes. 
Upon differentiation, the macrophages lose their ability to replicate and their defense functions are 
markedly enhanced, allowing them to participate in the inflammatory and immune responses (121). 
In the in vitro systems, Lipopolysaccharide (LPS) derived from gram-negative bacteria is 
considered to be the most potent activator of the macrophage secretory response (122). In our 
model, the stimulation with LPS leads THP1 to produce a Conditioned Medium (CM) enreached 
with different pro-inflammatory mediators, as shown in Figure 14.  
 
 
Figure 14: Explorative analysis of inflammatory mediators contained in the Conditioned Medium 
(CM) from PMA-differentiated THP1 after activation with LPS. Analysis was performed with a 
multiplex bead-based sandwich immunoassay to detect 14 inflammatory mediators; concentrations 
(pg/ml) are reported on a log10 scale. 
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Moreover, among the 6 most expressed pro-inflammatory mediators, we found that IL-6 
(p=0.0263), CXCL8 (p=0.004), TNF-α (p=0.0053) and MIP-1β (p<0.0001) significantly increased 
in the supernatant from LPS stimulated-THP1 compared to the unstimulated counterpart, while no 
differences were found for IFN-γ and MCP-1 (Figure 15).  
These results indicate that the CM produced by the PMA-differentiated THP1cells represents a 
complex pool of mediators, able to resembles a multi-inflammatory stimulus.  
 
Figure 15: Pro-inflammatory mediators in the conditioned medium (CM) from PMA-differentiated 
THP1 before and after activation with 50 ng/ml of LPS for 1h. Two replicates were analysed for 
each sample. Number of replicates (n)=2, number of independent experiments (N)=2. *= p<0.05, 
**=p<0.01, ***=p<0.001, unpaired t-test. 
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4.2 The Conditioned Medium promotes Notch1 pathway in CRC cells 
 
To determine whether the pro-inflammatory stimulus represented by the THP1-derived CM could 
drive the activation of Notch1 pathway, we incubated CRC cell lines with the CM and we analysed 
the effect of incubation both at a tradutional and a transcritpional level. 
4.2.1Effect of CM exposure on Notch1 pathway 
 
We found that upon 12 hours of CM exposure, the protein levels of the Notch1 Intracellular 
Domain (NICD) and the ligand of Notch1 importantly increases JAG1both in HT29 and HCT116 
cell lines (Figure 16). Notably, these data indicate that CM induces the activation of Notch1 
pathway, since it has been demonstrated that the binding of Jagged1 to the Notch1 receptor leads to 
the cleavage of Notch1 and to the consequent formation of the Intracellular Domain of Notch1 
(NICD) which then traslocated into the nucleus (61). 
 
Figure 16: Western Blot analyses for NICD and JAG1 in HT29 and HCT116 exposed to CM for 
12h. β-ACTIN was used as housekeeping protein. Each experiment was repeated at least three 
times. 
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4.2.2 Effect of CM exposure on transcriptional activity of Notch1 
 
To demonstrate that the up-regulation of the proteins involved in Notch1 pathway had an effective 
repercussion on the transcriptional activity of Notch1, we performed the qRT-PCR for the 
downstream target genes of Notch1. Particularly interesting was the evaluation of NRARP, since it 
has been demonstrated that it is the most reliable intestinal marker of Notch1 activation (72). 
We found that the CM-driven up-regulation of Notch1 pathway in HT29 and HCT116 cells was 
confirmed at mRNA level by a significant increase of the Notch1 target NRARP (p=0.0011 for 
HT29 and p=0.0023 for HCT116, CTRL vs CM), and a consensual decrease of ATOH1 (p=0.0027 
for HT29 and p=n.s for HCT116, CTRL vs CM) together with the increased expression of the 
Notch1 ligand JAG1 (p=0.0443 for HT29 and p=0.0012 HCT116, CTRL vs CM). Interestingly, no 
changes were observed in the level of the HES1 transcripts after Notch1 activation (Figure 17). 
 
 
Figure 17: qRT-PCR for JAG1, NRARP, HES1 and ATOH1 in HT29 and HCT116 cells incubated 
in CM.Statistical significance was calculated on logarithmic transformed values using unpaired t-
test, (n=3, N=4). *= p<0.05; **=p<0.01; ***=p<0.001. GAPDH was used as housekeeping gene. 
 
52 
 
4.3 Treatment with single proinflammatory mediators  
 
Since our hypothesis was that a multi-cytokine stimulus, rather than the effect of a single 
inflammatory mediator, induces the activation of Notch1 signaling in our model, we also tested the 
effect of single IL-6, CXCL8 or TNF-α exposures, given their abundance in the CM on HT29 cells. 
Then, we analysed NICD and JAG1 protein level. Effectively, our data show that the treatment with 
single cytokines did not increase the protein level of NICD and JAG1 (Figure 18).  
 
Figure 18: Western Blot analyses for NICD and Jagged1 in HT29 treated with single cytokines. IL-
6 (100 ng/ml ) CXCL-8 (1µg/ml ) or TNF-α (100 ng/ml) were used alone or in combination 
(COMB). βactin was used as housekeeping protein. 
 
4.4 The Conditioned Medium promotes EMT in CRC cells 
 
To date, it has been demonstrated that many cytokines are known to promote EMT in cancer cells 
(93), (123), (124), (125). Therefore, we decided to check EMT modulation in our model. In 
particular, we focused on ZEB1 and its direct target e-cadherin (CDH1), which play a central role in 
EMT, and on MMP9, since a modulation of NICD in MMP9-overexpressing cells has been recently 
demonstrated (80).  
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4.4.1Effect of CM exposure on proteins of EMT 
 
We found that the protein levels of ZEB1 and MMP9 were increased in both HT29 and HCT116 
treated with CM compared to the controls and, concomitantly, we found a modest reduction of E-
Cadherin (CDH1) upon CM exposure in HCT116 (Figure 19).  
4.4.2 Effect of CM exposure on transcriptional factors involved in EMT 
 
The results reported above were confirmed by a significant increase of ZEB1 (p=0.008 for HT29 
and p=0.0373for HCT116, CTRL vs CM) and MMP9 (p=0.0224 for HT29 and p<0.0001 for 
HCT116, CTRL vs CM) transcripts and by a consensual but not significant decrease of CDH1 in 
CM-treated cells compared to the controls (Figure 20).  
 
Figure 19: Western Blot analyses for ZEB1, MMP9, and CDH1 in HT29 and HCT116 exposed to 
CM. β-ACTIN was used as housekeeping protein. Each experiment was repeated at least three 
times. 
Taken together, these results suggest that the inflammatory microenvironment, represented by our 
cytokine-enreached-CM, can contextually activate Notch1 signaling and EMT both in HT29 and in 
HCT116 cells. 
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Figure 20:  qRT-PCR for ZEB1, MMP9 and CDH1 in HT29 and HCT116 cells incubated in CM. 
GAPDH was used as housekeeping gene. Statistical significance was calculated on logarithmic 
transformed values using unpaired t-test, (n=3, N=4 for HT29 and n=3, N=3 for HCT116). *= 
p<0.05; **=p<0.01; ***=p<0.001 
 
4.5 Notch1 up-regulation depends on MMP9 expression upon inflammation 
 
To better clarify the link between pro-inflammatory microenvironment, Notch1 signaling and EMT 
modulation, we tested the effect of CM both in Notch1- or MMP9-silenced HT29 cells. 
4.5.1 The effect of Notch1 silencing 
 
Intriguingly, our data show that the MMP9 induction upon CM exposure persisted even after 
Notch1 silencing. Accordingly, when we evaluated the mRNA expression of EMT mediators in 
CM-treated HT29 Notch1
-/-
 cells, we still found a significant up-regulation of ZEB1 and MMP9 
(p=0.0371 and p=0.0336, respectively) in Notch1
-/-
 CM vs Notch1
-/-
 CTRL (Figure 21), suggesting 
that the CM-driven induction of the EMT mediators was independent or precedes the Notch1 
activation. 
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Figure 21: Notch1
 
silenced cells under inflammatory conditions. (A) NICD protein level in HT29 
(CTRL) and NOTCH1 stably-silenced HT29 (NOTCH1
-/-
). (B) Western Blot analyses for MMP9 in 
NOTCH1-silenced HT29 cells exposed to CM. Each experiment was repeated three times. (C) qRT-
PCR for ZEB1, MMP9 and CDH1 in NOTCH1 silenced-HT29 cells incubated in CM. Statistical 
significance was calculated on logarithmic transformed values using unpaired t-test, (n=3, N=3). *= 
p<0.05; **=p<0.01; ***=p<0.001. 
 
4.5.2 The effect of MMP9 silencing 
 
To eventually demonstrate that MMP9 causes the activation of Notch1, we performed the  silencing 
of MMP9, expecting  that under this condition  the CM-driven NICD overexpression did not occur. 
Therefore, we transiently silenced MMP9 in HT29 cells. Importantly, we found that the protein 
level of NICD did not increase upon CM compared to its scramble control. Moreover, in MMP9-
silenced cells the transcriptional level of JAG1 and NRARP were not increased by CM stimulation 
(Figure 22).  
Taken together, our data show that inflammation up-regulates MMP9 which is in turn responsible 
for the activation of Notch1 pathway in CRC cells. 
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Figure 22: MMP9-silenced HT29 cells under inflammatory conditions MMP9 protein level in 
scramble and MMP9 transiently silenced-HT29 (MMP9
-/-
). (E) Western Blot analysis for NICD in 
MMP9-silenced HT29 cells exposed to CM for 12h. Each experiment was repeated twice. (F) qRT-
PCR for JAG1 and NRARP in MMP9-silenced HT29 and HCT116 cells incubated in CM, Statistical 
significance was calculated on logarithmic transformed values using unpaired t-test, (n=3, N=2). *= 
p<0.05; **=p<0.01; ***=p<0.001. GAPDH was used as housekeeping gene. 
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4.6 EPA-FFA treatment counteracts inflammatory-driven Notch1 activation 
 
Aiming at unravel new possible molecular mechanisms to explain the protective role of EPA in 
CRC, in this study EPA-FFA (ALFA, SLA Pharma Switzerland) was used for investigating its 
effect on CM-driven Notch1 and EMT activation.  
4.6.1 The establishment of EPA-FFA pre-treatment 
 
Firstly, HT29 and HCT116 were pre-treated for 72h with different dose of EPA-FFA in order to 
establish the range of toxicity of the substance. We found that EPA-FFA was non-cytotoxic up to 
150 μM, as established by MTT assay (Figure 23). For this reason, we decided to treat the cell lines 
with 50µM of final concentration, which was a very lower dose respect to the limit of toxicity.  
 
 
Figure 23: Cell viability of HT29 (left panel) and HCT116 (right panel) treated with EPA-FFA. 
Each experiment was performed in quintuplicate. Concentrations of EPA-FFA lower than 200 μM 
(HT29) and 150 μM (HCT116) did not cause cytotoxicity (ANOVA p<0.0001, Dunnet‟s test). 
Then, we tested the incorporation level of EPA into the cellular membrane, in order to demonstrate 
that EPA-FFA was effectively absorbed by the cells. We found that this treatment led to a 36% and 
19% of EPA incorporation into HT29 and HCT116 cellular membranes, respectively (Figure 24). 
We also optimized a prolonged treatment on HT29 (14 days of EPA-FFA) and observed that the 
levels of EPA incorporation were similar after 72h or 14 days of EPA-FFA (Table 2). Therefore, we 
decided to incubate our cells with EPA-FFA for 72h.  
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Figure 24: Relative abundance of EPA into the cellular membranes. Abundances for HT29 (left 
panel) and HCT116 (right panel) treated or not with 50 uM of EPA-FFA for 72h. 
 
 
TREATMENT Palmitic Stearic Oleic Linoleic Linolenic ARA EPA  DPA DHA  
CTRL 72h 22,3 23,0 41,5 7,6 0,4 2,56 0,64 0,8 1,06 
CTRL 72h 22,3 23,0 41,5 7,6 0,4 2,56 0,64 0,8 1,06 
EPA-FFA 72h 13,4 23,7 16,7 4,1 0,7 1,26 36,32 3,2 0,63 
EPA-FFA 72h 13,4 23,6 16,9 4,1 0,9 1,34 36,20 3,0 0,55 
CTRL 14days   22,9 22,2 43,2 4,9 0,5 2,91 0,99 1,1 1,28 
CTRL14days   16,3 19,4 52,2 5,5 0,4 3,27 0,92 0,8 1,16 
CTRL 14days   20,4 23,8 44,6 4,7 0,5 2,89 0,86 0,8 1,33 
EPA-FFA 14days   19,0 28,0 19,4 2,2 1,1 1,40 25,16 2,7 1,02 
EPA-FFA 14days   18,4 28,5 19,9 2,4 0,6 1,38 25,13 2,6 1,01 
EPA-FFA 14days   19,8 28,2 18,5 2,2 1,1 1,57 25,33 2,3 0,98 
 
Table 2: Relative abundances of Fatty acids after a 72h or 14 days treatment with EPA-FFA. 
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4.6.2 Effect of EPA-FFA treatment on CM-induced Notch1 pathway 
 
After 72h of EPA-FFA pre-treatment, HT29 and HCT116 were incubated with CM for 12h and 
Notch1 pathway was further analysed.  
In accordance to our hypothesis, EPA-FFA was able to reduce the CM-driven induction of JAG1 
and NICD both in HT29 and HCT116 cells (Figure 25 A and B). Accordingly, the EPA-FFA pre-
treatment alone did not significantly change the mRNA levels of JAG1, NRARP, HES1 and ATOH1 
(p=n.s. CTRL vs EPA) but was able to significantly counteract their increase in both HT29 and 
HCT116 CM-treated cells (p<0.01 and p<0.05 CTRL vs CM; p=n.s. CTRL vs EPA+CM, HT29 and 
HCT116 respectively), (Figure 25 C and D). However, pre-treatment with EPA-FFA did not reverse 
the profound ATOH1 down-regulation in HT29 cells (p<0.001 CTRL vs EPA+CM) obtained after 
CM incubation. 
Taken together, our data demonstrate  that pre-treatment with a non-cytotoxic dose of EPA-FFA 
was able to counteract the activation of Notch1 signaling obtained  upon  the incubation with the 
mixture of pro-inflammatory mediators represented by CM. 
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Figure 25: EPA-FFA represses inflammatory-driven NOTCH1 activation. Western Blot analyses 
for NICD and JAG1 in HT29 (A) and HCT116 (B) in incubated with CM (12h) and/or pre-treated 
with EPA-FFA (72h). β-ACTIN was used as housekeeping protein. (C) qRT-PCR for JAG1 
(ANOVA, p=0.0085), NRARP (ANOVA, p=0.0440), HES1 (ANOVA, p=n.s.) and ATOH1 
(ANOVA, p=0.0006) in HT29 (left panel) treated with EPA-FFA (72h) and/or CM (12h). (D) qRT-
PCR for JAG1 (p=0.0509), NRARP (p=0.0136), HES1 (p=n.s.) and ATOH1 (p=n.s.) in HCT116 
(right panel) treated with EPA-FFA (72h) and/or CM (12h). Data were corrected by logarithmic 
transformation and analyzed by One-way ANOVA and Tukey‟s Test for multiple pairwise 
comparisons (n=3, N=3). *= p<0.05, **=p<0.01, ***=p<0.001 compared to CTRL; #= p<0.05, 
##=p<0.01, ###=p<0.001 compared to CM; °= p<0.05, °°=p<0.01, °°°=p<0.001 compared to      
EPA-FFA. 
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4.7 Effect of EPA-FFA on CM-driven MMP9 activation 
 
To better clarify the role of EPA-FFA in our model, focusing in particular on the ability of EPA-
FFA to prevent the EMT phenotype induced through the incubation with CM, we assayed MMP9 
activity by gelatin zymography on CRC cells treated with CM alone, treated with EPA-FFA alone 
or treated with CM after a 72h EPA-FFA pre-treatment.  
The gelatin  zymography revealed that CM was able to induce an increase of MMP9 activity both in 
HT29 and HCT116 (p<0.05 and p=n.s. CTRL vs CM, respectively). Importantly,  treatment with 
EPA-FFA alone did not induced changes in term of MMP9 activity, but we found that pre-treatment 
with EPA-FFA reduces the CM-induced MMP9 activity in HCT116 (p=n.s. CM vs EPA+CM), 
although not reaching a statistical significance. 
Interestingly, we also found a decreasing trend of mRNA levels for ZEB1 (p=n.s. in HCT116 and 
HT29) and MMP9 (p<0.05 in HCT116, CTRL vs CM; p=n.s. CTRL vs EPA+CM; p=n.s. in HT29) 
in samples pre-treated with EPA-FFA and incubated with CM compared to samples only incubated 
with CM, while EPA-FFA alone did not induced variations in the expression of tested mRNA 
(Figure 26B).  
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Figure 26: Effect of EPA-FFA on CM-induced MMP9 activation and invasion. (A) Gelatin 
zymography in response to EPA-FFA (72h) and/or CM (12h) treatment in HT29 (left panel) and 
HCT116 (right panel). Bars indicate Mean±SEM of densitometric values of MMP9 form 
normalized to the corresponding CTRL values (ANOVA p=0.0067 for HT29 and p=0.0473 for 
HCT116, (N=2). (B) qRT-PCR for ZEB1 (ANOVA p=n.s for HT29 and HCT116), MMP9 
(ANOVA p=n.s for HT29 and p=0.0525 for HCT116) and CDH1 (ANOVA, p=n.s for HT29 and 
HCT116) in HT29 and HCT116 EPA-FFA and/or CM treated cells (n=2; N=3). Analyses were 
performed on logarithmic transformed data. After the ANOVA global test, Tukey‟s post hoc test 
was used for multiple pairwise comparisons. *= p<0.05, **=p<0.01, ***=p<0.001 compared to 
CTRL; #= p<0.05, ##=p<0.01, ###=p<0.001 compared to CM; °= p<0.05, °°=p<0.01, °°°=p<0.001 
compared to EPA-FFA. 
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4.8 EPA-FFA treatment counteracts cell invasion 
Finally, we decided to analyse the phenotypical effect of CM and EPA-FFA treatment on CRC 
cells. We opted for the evaluation of  the invasive behaviour, since it is known that EMT led to an 
augmented capability to invade and that this latter is one of the dominant program in human colon 
cancer (97). 
We achieved that CM significantly induced  invasiveness in both HT29 and HCT116 (p<0.05 for 
both compared to controls) and pre-treatment with EPA-FFA strongly reduced this effect (p=n.s. for 
both compared to controls), as shown in Figure 27. 
In conclusion, these data indicate that in our in vitro model a non-cytotoxic treatment with EPA-
FFA is able to reduce the Epithelial to Mesenchymal Transition and to prevent invasiveness driven 
by inflammatory conditions. 
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Figure 27: Matrigel invasion assay of HT29 and HCT116 treated with EPA-FFA and/or CM. Bars 
indicate Mean±SEM of number of invasive cells/chamber normalized to the corresponding CTRL 
values (ANOVA p=0.0284 for HT29 and p=0.0007 for HCT116), (n=5, N=2). Analyses were 
performed on logarithmic transformed data. After the ANOVA global test, Tukey‟s post hoc test 
was used for multiple pairwise comparisons. *= p<0.05, **=p<0.01, ***=p<0.001 compared to 
CTRL; #= p<0.05, ##=p<0.01, ###=p<0.001 compared to CM; °= p<0.05, °°=p<0.01, °°°=p<0.001 
compared to EPA-FFA. 
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5. DISCUSSION 
 
The aim of this study was to investigate the role of a complex inflammatory stimulus, represented 
by the mix of mediators obtained  in the Conditioned Medium (CM) from stimulated macrophages, 
on the modulation of Notch1 pathway. The data presented here show that the exposure of CRC cells 
to CM strongly up-regulates Notch1 signaling, inducing changes in Epithelial to Mesenchymal 
Transition (EMT) markers and enhancing cell invasion; we also found that Notch1 pathway 
depends on MMP9 expression under inflammatory conditions. Moreover, this work aimed at 
studying the possible protective role of Eicosapentaenoic Acid in the free fatty acid form (EPA-
FFA) on the above-mentioned  molecular mechanism. We demonstrate, for the first time, that the 
treatment with EPA-FFA, used at a non-cytotoxic concentration, is able to counteract the effect of 
inflammation both on Notch1 cascade and on cell invasion.  
A  growing interest in the role of the inflammatory microenvironment in tumorigenesis has been 
recently emerged, and, with the purpose of studying the related molecular mechanisms, the use of a 
Conditioned Medium has already been employed (CM), (126). This approach points at analysing 
the combined effect of different inflammatory mediators, instead of the role of single molecules, 
thus representing a model more similar to the in vivo scenarios. Notably, it has been already 
reported that the inflammatory mediators expressed in our CM are crucially involved both in CAC 
and sporadic CRC (47). Interestingly, when we applied each single pro-inflammatory factor (IL-6, 
CXCL8 and TNF) to HT29 and HCT116, we did not obtain the same level of Notch1 induction 
found after the incubation with CM, even if  these cytokines were chosen because of their major 
abundance in CM. We observed a similar result also combining  IL-6, CXCL8 and TNF, 
indicating that the stimulus represented by CM  is so complex that cannot be reproduced only by 
four mediators. Similarly to the present work, in which is shown that CM up-regulates the Notch1 
pathway in CRC cells, Lin and colleagues found a marked increase of Notch1 by incubating CRC 
cells in a Conditioned Medium collected from cultured mesenchymal stem cells. However, albeit 
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they reported an increase of full length Notch1 expression due to IL-6 treatment, in our study  the 
level of the active domain of Notch1 protein was not affected by this cytokine (82). In our model, 
the induction of Notch1 pathway is confirmed by the concordant modulation of its downstream 
targets NRARP and ATOH1, while no changes were observed for HES1, in agreement with the 
finding that it can be also controlled by Notch1-independent signaling pathways (127). Many other 
reports indicate a pro-tumorigenic role of Notch1 in relation to inflammation in models of CRC. For 
instance, it has been reported that the crosstalk between Notch1 and IKKα signaling, which plays an 
essential role in inflammation, exacerbates the proliferation and inhibits the apoptosis in HT29 and 
other cell lines (128). Nevertheless, it has been reported that the blockage of Notch1 cascade has a 
protective effect toward CRC development in the ApcMin/+ mouse model of FAP (74). More 
recently, an elegant study from Taniguchi et al. showed that the co-receptor of IL-6 gp130 induces 
the activation of Notch1 without involving  the classic gp130 effector STAT3, thus stimulating the 
cellular proliferation (83). However, the involvement of Notch1 pathway in intestinal cancer-related 
inflammation still represents a certain enigma. Indeed, our group has recently found that Notch1 
signaling is down-regulated in the azoxymethane-dextran sodium sulfate (AOM-DSS) model of 
CAC, probably as effect of the epithelial damage due to DSS administration (114). Accordingly, 
Kim et al. have shown that the induced activation of Notch in the ApcMin/+ mouse model 
converted intestinal high-grade adenoma into low-grade adenoma, indicating a negative effect on 
cancer progression; they further demonstrated that this mechanism is mediated by the negative 
control of NRARP on WNT target genes (72). The involvement of -catenin in concomitance to the 
protective role of Notch has been demonstrated also in our in vivo model of colitis-associated 
cancer (CAC), suggesting that these pathways (Notch and WNT) cooperate also under a certain 
setting of inflammatory conditions (114).  Intriguingly, these opposing effects of inflammation on 
Notch1 signaling might underlie different mechanisms through which inflammation drives cancer 
development during sporadic CRC and CAC. 
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Then, the present work shows that CM is able to enhance the EMT in CRC cells, in particular 
regulating ZEB1 and MMP9 both at a protein and RNA level. Interestingly, Chanrion and 
colleagues found that the activation of Notch1 and the concomitant p53 deletion triggered EMT in 
the mouse gut (129); however, since HCT116 and HT29 have respectively wild type and mutant 
p53, we hypothesize that, in our model, the inflammation-driven EMT mechanism does not depend 
on p53. Even though it is well established that Notch1 signaling can be involved in the induction of 
EMT (92), less is known about the possible role of EMT as activator of Notch1. Noteworthy, in this 
study we demonstrate that inflammation induces the MMP9 overexpression and, as a consequence, 
the activation of the Notch1 pathway occurs. Accordingly, several reports acknowledge the 
tumorigenic role of MMP9 on Notch signaling pathway. For instance, it has been recently reported 
that the up-regulation of MMP9, linked to the activity of the protein Claudin-1, induces the Notch 
signaling activation, leading to the decrease of goblet cell number and thus enhancing the 
susceptibility to mucosal inflammation in the DSS-induced mouse model of colitis (84). 
Intriguingly, Garg and his group has recently shown that MMP9 up-regulation results in augmented 
levels of NICD in the AOM/DSS mouse model of CAC, but they attribute a protective role to this 
mechanism, in accordance with our previous results of Notch1 signaling in AOM-DSS treated mice 
(80). In contrast, as already discussed, the present study could  mimic the effect of the inflammatory 
milieu on sporadic CRC, which deeply differs from the pro-inflammatory stimulus involved in 
CAC, probably explaining these opposite results. 
In the last decades, Omega-3 polyunsaturated fatty acids (ω-3 PUFAs), and in particular the 
Eicosapentaenoic Acid (EPA), have been extensively studied for their possible role in the 
prevention and treatment of both inflammatory diseases and cancer (130). Indeed, it has been 
demonstrated that EPA is able to modulate several molecular pathways (110). One of the best 
characterized mechanisms of action is based on the capability of EPA to competing with the 
Arachidonic Acid, which is the substrate for the enzymatic action of COX-2; in this way, EPA 
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induces the reduction of the proinflammatory Prostaglandin of the series E2 in favour of the anti-
inflammatory series E3 (131). Recently, we also demonstrated that the dietary supplementation of 
EPA, used as a free fatty acid in an extra pure formula with a higher level of bioavailability (EPA-
FFA), significantly protected from cachexia and dramatically suppressed polyp number, size and 
burden in ApcMin/+ mice, by inhibiting COX-2 expression. Moreover, we showed that in the 
ApcMin/+ EPA-FFA was able to reduced β-catenin nuclear translocation, cell proliferation, and to 
induce an increase in apoptosis (113). Nevertheless, we recently found that EPA-FFA can also 
modulate the microbiota profile in the AOM/DSS mouse model (114). These findings suggest that 
EPA-FFA could regulate many unknown molecular pathways. Therefore, in the present model of 
inflammatory-driven CRC, we performed a prolonged pre-treatment with EPA-FFA both for 72h or 
14 days on HT29 and HCT116 cells. We found that the incorporation of EPA into the cellular 
membrane was similar in these conditions, indicating that the maximum incorporation was reached 
very quickly, probably due to the FFA formulation. Importantly, our data show for the first time 
that EPA-FFA is able to hamper the CM-driven up-regulation of NICD and JAG1 in CRC cells and 
tends to inhibit the MMP9 activity in HCT116. Also, EPA-FFA counteracts the CM-induced 
cellular invasiveness in both cell lines, whereas HCT116 cells are known to exhibit higher invasion 
capability than HT29 cells (132). Similarly, Cheng-Chung Li and his group found that a treatment 
with EPA and DHA decreased MMP9 level in prostate cancer cells (133). It is important to note 
that, although the above-mentioned differences between our previous AOM-DSS in vivo work and 
the present in vitro study, EPA-FFA showed the same capability to modulate Notch1 signaling in 
both models (114). 
In conclusion, we demonstrate for the first time that inflammation, inducing the MMP9 
overexpression, strongly activates the Notch1 pathway and that this mechanism could be prevented 
by EPA-FFA in CRC. 
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